Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. LAMZEDE (velmanase alfa)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

LAMZEDE (velmanase alfa)

Medicine - Posted on Jan 10 2025
Active substance (DCI)
  • velmanase alfa
history (4)
  • 12/11/24

    LAMZEDE (velmanase alfa) - Alpha-mannosidosis

    Summary of opinion Favourable opinion: for reimbursement in the non-hospital setting, for maintenance of reimbursement in th...
    CAV :
    54321
    icône flèche
  • 1/19/22

    LAMZEDE (velmanase alfa)

    Key points Favourable opinion for maintenance of reimbursement in the enzyme replacement therapy of non-neurological manifes...
    CAV :
    54321
    icône flèche
  • 12/12/18

    LAMZEDE (velmanase alpha), enzyme

    Moderate clinical benefit in non-neurological manifestations of mild to moderate alpha-mannosidosis and minor clinical added...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • A16AB15
Manufacturer
CHIESI SA
Presentation

LAMZEDE 10 mg, poudre pour solution pour perfusion
1 flacon en verre de 10 mg (CIP : 34009 550 519 6 1)
1 flacon en verre de 10 mg (CIP : 34009 302 829 4 6) 

All our publications
    Congenital, genetic and rare diseases Drug therapy Metabolic diseases Paediatrics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
ME3t3MGtpDrACrvy